Drug Manufacturers - Specialty & Generic · Healthcare
Board Member
2015-12-22–present
Board Member
Emergent BioSolutions Inc. (EBS)Equibles does not estimate personal net worth.
Get an email with a short summary when Emergent BioSolutions Inc. publishes a filing, an earnings call transcript or a press release.
Get EBS alertsFuad El-Hibri is recorded as Board Member at Emergent BioSolutions Inc. (EBS) since December 22, 2015. Earlier roles on record: Chairman at Aptevo Therapeutics Inc. (APVO) until April 1, 2022. The proxy statement of Emergent BioSolutions Inc. reports total compensation of $3,515,977 for Fuad El-Hibri in fiscal 2021, including a base salary of $1,190,867. Disclosed compensation is on record for 5 fiscal years. Fuad El-Hibri has spoken on 17 earnings calls across 1 company, most recently for Emergent BioSolutions Inc. on December 31, 2011. Emergent BioSolutions Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Emergent BioSolutions Inc. includes Daniel J. Abdun-Nabi (CEO, COO and Board Member), Joseph C. Papa (CEO and Board Member), Joseph Papa (CEO and Board Member) and 7 others.
“For my prepared comments, I will review our financial performance for 2011, address the forecasts for 2012, including revenue expectations for the first quarter and discuss the current status of the company.”
“During the third quarter, we continued to execute on our operating plan. We manufactured and delivered doses of BioThrax into the SNS. We advanced the development of our infectious disease, oncology, and autoimmune programs, and we made progress on Building 55 scale up.”
“In my prepared comments, I will review our financial performance for the second quarter, discuss our revised full-year 2011 guidance, provide guidance on third quarter revenue, and highlight milestones related to our advanced stage development programs.”
“In my prepared comments, I will review our financial performance for the first quarter of 2011, provide guidance on the second quarter revenue, discuss relevant updates to our business, and highlight key near-term milestones.”
“For my prepared comments, I will review our financial performance for 2010 and forecast for 2011. Discuss major accomplishments achieved during 2010 and highlight key milestones for 2011.”
2015-12-22–present
Start not stated–2012-04-01
Start not stated–2022-04-01
Start not stated–2022-04-01
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member
2015-12-22–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Emergent BioSolutions Inc. (EBS) | Former Executive Chairman of theBoard of Directors | $1,190,867 | $3,515,977 |
| 2020 | Emergent BioSolutions Inc. (EBS) | Former Executive Chairman of theBoard of Directors | $1,192,202 | $3,213,484 |
| 2019 | Emergent BioSolutions Inc. (EBS) | Former Executive Chairman of theBoard of Directors | $1,131,577 | $3,010,062 |
| 2018 | Emergent BioSolutions Inc. (EBS) | Executive Chairman of the Board of Directors | $1,047,031 | $2,970,218 |
| 2017 | Emergent BioSolutions Inc. (EBS) | Executive Chairman of the Board of Directors | $1,023,954 | $2,567,482 |